Mereo BioPharma Group

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MREO and other ETFs, options, and stocks.

About MREO

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649).

CEO

Denise Vera Scots-Knight

CEODenise Vera Scots-Knight

Employees

Employees39

Headquarters

London, Greater London

HeadquartersLondon, Greater London

Founded

2015

Founded2015

Employees

Employees39

MREO Key Statistics

Market cap

48.40M

Market cap48.40M

Price-Earnings ratio

-1.81

Price-Earnings ratio-1.81

Dividend yield

—

Dividend yield—

Average volume

801.57K

Average volume801.57K

High today

$0.3176

High today$0.3176

Low today

$0.2969

Low today$0.2969

Open price

$0.3023

Open price$0.3023

Volume

617.43K

Volume617.43K

52 Week high

$2.37

52 Week high$2.37

52 Week low

$0.20

52 Week low$0.20

MREO News

Seeking Alpha 4d

Mereo BioPharma Group GAAP EPS of -$0.01 in-line, revenue of $0.80M

Earnings News Mereo BioPharma Group GAAP EPS of -$0.01 in-line, revenue of $0.80M Nov 09, 2026, 8:12 AM ET Mereo BioPharma Group plc (MREO) Stock By : Urvi Shah...

Analyst ratings

67%

of 6 ratings

Buy

66.7%

Hold

16.7%

Sell

16.7%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.